Journal September 25, 2026 6 min read

What markers track cerebral blood flow?

Cerebral blood flow is tracked with a small set of imaging, Doppler and biochemical markers. This page maps the markers named in registered trials and peer-reviewed studies, and flags where the evidence is animal-only or

peptides-pro Editorial

Cerebral blood flow (CBF) is the volume of blood delivered to brain tissue per unit time, usually expressed as millilitres per 100 grams of brain tissue per minute. In the research literature it is tracked through a defined set of markers rather than a single readout: Doppler-derived indices such as the cerebral Doppler resistive index, perfusion-based imaging measures of regional CBF, and biochemical markers of the vascular and metabolic environment in which flow is regulated. The evidence block for this page does not supply a sequence, formula or molecular weight for CBF itself, because CBF is a physiological parameter and not a compound; the identifiers that appear in the evidence belong to the interventions studied against it, such as nicotinamide riboside, pterostilbene, citicoline, and the ACTH-like peptides ACTH(4-7)PGP (Semax) and ACTH(6-9)PGP.

The work gathered here centres on the neurovascular and metabolic signalling that couples neuronal activity to local blood delivery, including NAD⁺-dependent metabolism, reactive oxygen species (ROS) signalling, and peptide-mediated neuroprotection after experimental ischemia.

Research Studies

Citicoline and cerebral Doppler resistive index in neonatal hypoxic-ischemic encephalopathy

A registered trial is designed to determine the efficacy of citicoline in improving cerebral blood flow parameters and neurological status among neonates with hypoxic-ischemic encephalopathy, using the Doppler resistive index and the Sarnat-Sarnat score after 72 hours of therapy [2]. This is a clinical population — neonates — and the marker of interest is a Doppler-derived index rather than a perfusion value.

Nicotinamide riboside and cerebral blood flow in amnestic mild cognitive impairment

A 12-week double-blind, randomised, placebo-controlled pilot study evaluated the safety, tolerability and preliminary efficacy of the NAD⁺ precursor nicotinamide riboside for enhancing cognitive function and cerebral blood flow in adults with amnestic mild cognitive impairment. Forty-two participants completed the study (NR = 22, placebo = 20); adherence was similar between groups with no serious adverse effects, and blood NAD⁺ increased twofold in the NR group. There were no improvements in the cognitive outcomes reported [4]. The population here is older adults with aMCI, and the finding is a null result on the reported endpoints.

Avocado consumption and cerebral blood flow in pre-diabetic adults

A randomised crossover intervention study is assessing the effect of 12-week daily avocado consumption on cerebral blood flow and markers of cardio- and vascular health in both the periphery and the brain, in pre-diabetic individuals with overweight or obesity. A secondary objective is to assess effects on brain insulin sensitivity after intranasal insulin delivery, vascular function, markers of metabolic health, cognition and psychological well-being. Thirty-four men and women aged 40–75 years are to participate [1]. This trial treats CBF as one marker within a broader cardio-metabolic panel.

Dasatinib and quercetin and cerebral blood flow regulation in adults at risk of Alzheimer's disease

A pilot study is evaluating the safety and feasibility of intermittent doses of dasatinib and quercetin in older adults at risk of Alzheimer's disease, and whether administration may improve cerebral blood flow regulation, mobility and cognition [8]. The stated marker is CBF regulation rather than absolute flow, and the population is older adults at risk of AD.

Reactive oxygen species and cerebral blood flow in healthy adults

A study enrolling 30 healthy participants (15 male, 15 female) aged 18–40 years is designed to test the role of reactive oxygen species in regulating cerebral blood flow, with participants attending two study visits over a six-month period [7]. This is a mechanistic study in healthy adults, and it positions ROS as a regulator of CBF rather than as a downstream marker of it.

Pterostilbene derivatives and blood-brain barrier protection in cerebral ischemia-reperfusion injury

Pterostilbene is a small molecule stilbenoid and a dimethyl analogue of resveratrol that exerts blood-brain barrier protection in cerebral ischemia-reperfusion injury. A structural optimisation study generated a series of pterostilbene derivatives and investigated their anti-ischemic activities both in vitro and in vivo, using ADMET prediction for drug-likeness, MTT cell viability analysis in neuroblastoma cells (SH-SY5Y) and brain microvascular endothelial cells, and in vivo work, aiming to identify candidates with improved efficacy and safety relative to pterostilbene [5]. The endothelial and barrier readouts here are in vitro and animal-based; they are not human CBF measurements.

ACTH-like peptides and penumbral gene expression after experimental stroke

Ischemic stroke results from a disruption of cerebral blood flow, and adrenocorticotropic hormone serves as the basis for synthetic peptides developed as neuroprotective agents for stroke therapy. In a rat transient middle cerebral artery occlusion model, RNA-Seq was used to identify differentially expressed genes associated with ACTH(4-7)PGP (Semax) and ACTH(6-9)PGP in the ipsilateral frontal cortex at 4.5 hours after occlusion; a later analysis examined the penumbra-associated frontal cortex and the actions of the same peptides at 24 hours after tMCAO [6]. This evidence is animal-only and describes gene expression in brain tissue, not a flow marker measured in humans.

Markers compared across the evidence

Marker	What it measures	Population or model in the evidence	Source
Cerebral Doppler resistive index	Doppler-derived flow resistance	Neonates with hypoxic-ischemic encephalopathy	[2]
Cerebral blood flow (imaging)	Regional perfusion	Adults with amnestic mild cognitive impairment	[4]
Cerebral blood flow and vascular markers	Peripheral and brain vascular health	Pre-diabetic adults with overweight or obesity	[1]
Cerebral blood flow regulation	Dynamic flow control	Older adults at risk of Alzheimer's disease	[8]
Reactive oxygen species	Regulator of CBF	Healthy adults aged 18–40	[7]
Blood-brain barrier and cell viability	Barrier protection, endothelial and neuronal viability	In vitro (SH-SY5Y, brain microvascular endothelial cells) and in vivo	[5]
Penumbral gene expression	Transcriptional response to ischemia	Rat tMCAO model	[6]

Supporting evidence on lifestyle and systemic contributors

A scoping review examined the effect of the Mediterranean diet combined with physical activity on cognitive function in older adults, reporting that cognitive impairment and dementia are increasing among older adults with limited pharmacological treatments available, and that modifiable lifestyle factors — particularly diet and physical activity — are promising preventive targets [9]. Separately, a multimodal neuroimaging study applied an integrated information decomposition framework to resting-state fMRI from 48 heart failure patients to characterise altered brain information processing, noting that heart failure is frequently accompanied by cognitive and affective impairments whose neural mechanisms remain poorly defined [10]. Neither source reports a direct CBF marker, and both are included here as context for the systemic and lifestyle factors that surround flow measurement.

If you are reading this for personal health reasons

The materials described on this page are sold for laboratory research use only. We do not provide dosing information or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician.